Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035
30 nov. 2021 08h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...